Globe Life Inc (GL)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Whoever buys today bets that Globe Life's high return on capital more than justifies the controversy discount and that the class action ends without material damage — and pays only a good 8 to 9 times operating earnings for it, backed by growing book value and ongoing buybacks. Whoever waits may miss the cheapest entry but can check every quarterly report (10-Q) and the "Commitments and Contingencies" note for whether the case is progressing: clarity on the class action and no new government footnotes would be the evidence. The decision is yours.
symbol.quality_note
Globe Life insures lower-middle to middle-income America with life and supplemental health policies, and it shows up in our Joshua growth scanner (rank 20, as of July 17, 2026). We read the annual reports (10-K) for 2024 and 2025 and the quarterly report (10-Q) as of March 31, 2026: a profit machine with a 20.9 percent return on equity, a book value that rose 19 percent, and $685 million of share buybacks in 2025 — but also an April 2024 short-seller episode, a securities class action that survived the company's dismissal motion in September 2025, and government footnotes that vanished between two annual reports. Not investment advice — just the question of what a pristine balance sheet is worth when the fight is not about the numbers but about how they are made.
Read the analysis
Stock Watch
This analysis is as of July 17, 2026. Stock Watch will tell you what's changed at GL since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 21 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 182.30 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
Uses AIGlobe Life Inc. (NYSE: GL) ist ein Lebens- und Krankenzusatzversicherer ohne KI-Umsätze. Der Geschäftsbericht 10-K für 2025 nennt künstliche Intelligenz ausschließlich im Kontext der eigenen IT-Modernisierung („innovative, responsible, and secure use of artificial intelligence“) sowie als allgemeines operatives IT-Risiko. Das belegt einen internen, operativen KI-Einsatz, aber kein KI-Produkt und keine KI-Umsatzquelle. Vorrangprüfung: kein Verkauf von KI; der Risk-Factor-Hinweis auf „responsible use of emerging technologies, including artificial intelligence“ ist eine allgemeine Technik-/Betriebsrisiko-Floskel ohne konkreten Bezug auf eine Bedrohung des Versicherungs-Geschäftsmodells (kein „bedroht“). Erste zutreffende Kategorie nach Vorrang ‚Verkauft > Bedroht > Nutzt > Neutral‘ ist damit ‚Nutzt KI‘.
View the full file — quotes, sources, reviewed filings
„This modernization includes the innovative, responsible, and secure use of artificial intelligence (“AI”)."
Diese Modernisierung umfasst den innovativen, verantwortungsvollen und sicheren Einsatz künstlicher Intelligenz („KI“).
„The failure to maintain effective information systems or manage responsible use of emerging technologies, including artificial intelligence, could adversely affect our financial condition and results of operations at the Company."
Das Versäumnis, wirksame Informationssysteme zu unterhalten oder den verantwortungsvollen Einsatz neuer Technologien einschließlich künstlicher Intelligenz zu steuern, könnte die Finanzlage und die Geschäftsergebnisse des Unternehmens beeinträchtigen.
Filings Reviewed: 10-K 2026-02-25 · 10-Q 2026-05-07 · 10-K 2025-02-26
Rated on July 17, 2026 · How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 4.8% failed
- More than 10% revenue growth is expected for the coming year 6.1% failed
- Share count grows by less than 3% a year -6.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 24.7% failed
- Gross margin at 40% or higher and without meaningful erosion 33.4% failed
- Goodwill from acquisitions does not grow faster than revenue 1.6% passed
- Net debt below twice EBITDA 15,423 m net cash passed
- Operating cash flow covers the profits of the last three years 1,079 m passed
- Return on capital at 15% or higher, or up versus two years ago 5.1% passed
- Insiders hold at least 10% or are net buyers 0.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 6.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15.70 | 15.55 – 15.76 | 6,390 | 8.1% | 11 |
| 12/31/2027 | 16.52 | 16.03 – 16.85 | 6,804 | 5.2% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.83 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 3.01 | 4.60 | 1,466 | 3.60 | 17.40 | 337 | 322 |
| 2025: Q1 | 3.01 | 12.70 | 1,480 | 4.50 | 17.20 | 432 | 420 |
| 2025: Q2 | 3.05 | 10.90 | 1,481 | 2.80 | 17.10 | 308 | 295 |
| 2025: Q3 | 4.73 | 37.50 | 1,513 | 4.00 | 25.60 | 306 | 209 |
| 2025: Q4 | 3.29 | 9.30 | 1,524 | 3.90 | 17.50 | 351 | 330 |
| 2026: Q1 | 3.39 | 12.50 | 1,560 | 5.30 | 17.30 | 421 | 396 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3,935 | 772 | 550 | 4.49 | 1,399 | 4,567 | 21,436 |
| 2017 | 4,156 | 924 | 1,454 | 12.22 | 1,429 | 6,231 | 23,475 |
| 2018 | 4,304 | 954 | 701 | 6.08 | 1,278 | 5,415 | 23,096 |
| 2019 | 4,528 | 930 | 761 | 6.83 | 1,364 | 7,294 | 25,977 |
| 2020 | 4,738 | 895 | 732 | 6.82 | 1,476 | 8,771 | 29,047 |
| 2021 | 5,113 | 911 | 745 | 7.22 | 1,438 | 8,643 | 29,768 |
| 2022 | 5,215 | 997 | 740 | 7.47 | 1,422 | 3,950 | 25,987 |
| 2023 | 5,448 | 1,194 | 971 | 10.07 | 1,482 | 4,487 | 28,052 |
| 2024 | 5,778 | 1,327 | 1,071 | 12.63 | 1,402 | 5,306 | 29,076 |
| 2025 | 5,999 | 1,463 | 1,161 | 14.36 | 1,396 | 5,975 | 30,814 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
A 20.9 percent return on equity (2025), net operating income per share up 17 percent to $14.52, premium up 5 percent to $4.89 billion — the earnings curve does not bend in any of the three years, not even in 2024, the year of the short-seller episode (annual report 10-K for 2025).
Book value per share up 19 percent to $74.17 (excluding AOCI $96.16), plus $685 million of buybacks in 2025 at an average of $126.41 — management concentrates earnings per share consistently, backed by $5.97 billion of equity.
From the April 2024 short-seller episode, one securities class action and five derivative suits are pending; the company's motion to dismiss was denied on September 29, 2025, and the size of any loss cannot be reasonably estimated per the report (10-K 2025, Note 5). The dispute is about the narrative around the numbers, not the numbers themselves.
The engine is tens of thousands of independent agents whose sales practices are at the center of the allegations — a reputational and regulatory risk that is hard to quantify and steer. The 2024 report also named a DOJ subpoena and an SEC inquiry that no longer appear in the 2025 report (resolution likely, but not expressly confirmed).
At the average 2025 repurchase price of $126.41, the market pays a good 8 to 9 times operating earnings and about 1.3 times AOCI-adjusted book value — low for a 16 to 21 percent return on capital. The discount is the price of the controversy, whose outcome no filing quantifies.
Globe Life is one of the most reliable profit machines in U.S. insurance: a 20.9 percent return on equity, growing book value, $685 million of share buybacks — and an earnings curve that did not bend even in 2024, the year of the short-seller episode. But its biggest risk sits not in the balance sheet, but in trust: from the April 2024 episode a securities class action is pending that survived dismissal in September 2025, and the allegations target the sales practices of tens of thousands of independent agents. Whoever invests here buys a first-rate compounder at a controversy price — and bets that a decentralized sales apparatus comes cleanly through the litigation. Not investment advice.
- GL reached our research list via the Joshua growth scanner (rank 20, as of July 17, 2026); unlike most hits, Globe Life is no growth sprinter but a capital compounder with a high return on equity.
- Metrics such as net operating income and book value "excluding AOCI" are non-GAAP measures (defined by management). They are common and meaningful at insurers but are not a GAAP standard; net income ($1.16 billion in 2025) is the directly comparable GAAP figure.
- The valuation anchor is the average 2025 repurchase price ($126.41), deliberately dated and evergreen; daily prices are not a buy argument. Globe Life's fiscal year matches the calendar year (ends December 31). Identity verified via EDGAR (CIK 0000320335, formerly Torchmark Corporation).
About the Company
Globe Life Inc. bietet über ihre Tochtergesellschaften diverse Lebens- und ergänzende Krankenversicherungsprodukte für Familien mit niedrigem und mittlerem Einkommen in den USA an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 3,695 |
| Headquarters | McKinney, TX |
| Address | 7677 Henneman Way, 75070 McKinney, United States |
| Phone | 972 569 4000 |
| Website | home.globelifeinsurance.com |
| IPO Date | 30. Dec 1987 |
| ISIN | US37959E1029 |
| Stock Split | 3:2 on 07/02/2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank Martin Svoboda | Co-Chairman & Co-CEO | 1962 |
| James Matthew Darden | Co-Chairman & Co-CEO | 1971 |
| Thomas Peter Kalmbach | Executive VP & CFO | 1965 |
| Robert Edward Hensley | Executive VP & Chief Investment Officer | 1968 |
| Robert Brian Mitchell J.D. | Executive VP, General Counsel & Chief Risk Officer | 1964 |
| Michael Clay Majors | Executive VP & Chief Strategy Officer | 1963 |
| M. Shane Henrie | Corporate Senior VP & Chief Accounting Officer | 1974 |
| Christopher Kyle Tyler | Executive VP & Chief Information Officer | 1974 |
| Dolores L. Skarjune | Executive VP & Chief Administrative Officer | 1966 |
| Stephen Mota | Senior Director of Investor Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Sell | 2,790 | 181.81 | 507,264 |
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Sell | 2,650 | 181.23 | 480,255 |
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Sell | 4,840 | 180.08 | 871,578 |
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Sell | 10,720 | 179.30 | 1,922,066 |
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Other | 11,000 | 120.49 | 1,325,390 |
| 30. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Other | 10,000 | 103.23 | 1,032,300 |
| 29. Jul 2026 | Majors Michael Clay | EVP - Chief Strategy Officer | Sell | 3,500 | 179.35 | 627,722 |
| 29. Jul 2026 | Majors Michael Clay | EVP - Chief Strategy Officer | Sell | 33,500 | 178.56 | 5,981,804 |
| 29. Jul 2026 | Majors Michael Clay | EVP - Chief Strategy Officer | Other | 37,000 | 103.23 | 3,819,510 |
| 28. Jul 2026 | Kalmbach Thomas Peter | EVP & CFO | Sell | 3,797 | 179.42 | 681,246 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.